Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

Netflix Hosting Squid Game Reality Show: How To Apply And How Much You Can Win

If you think you have the skills to master a game of “red light, green light,” Netflix Inc (NASDAQ: NFLX) might cast you in the upcoming reality series based on the popular streaming hit “Squid Game.”

Benzinga

$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,600 Today

Marvell Tech (NASDAQ:MRVL) has outperformed the market over the past 20 years by 4.75% on an annualized basis producing an average annual return of 11.61%. Currently, Marvell Tech has a market capitalization of $41.24 billion.

Benzinga

Why This Chesapeake Energy Analyst Is Bullish: ESG, Buybacks And More

Due to Chesapeake Energy (NASDAQ: CHK) restructuring to lower its costs, it will be focusing on bolstering its balance sheet, as it is a legacy company, a Credit Suisse analyst said Tuesday.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Here's How Much You Would Have Made Owning Monster Beverage Stock In The Last 15 Years

Monster Beverage (NASDAQ:MNST) has outperformed the market over the past 15 years by 11.71% on an annualized basis producing an average annual return of 17.93%. Currently, Monster Beverage has a market capitalization of $46.64 billion.

Benzinga

Apple Ramps Up Sports Content With Major League Soccer Deal: What Investors And Sports Fans Should Know

Technology giant and streaming company Apple Inc (NASDAQ: AAPL) signed a deal with Major League Soccer (MLS) on Tuesday. Here are the details.

Benzinga

MorphoSys Stock Skyrockets On Entering Equity Participation and License Agreements With HIBio

MorphoSys AG (NASDAQ:MOR) and Human Immunology Biosciences, Inc. (HIBio), a biotechnology company, have established an equity participation agreement and license agreements to allow HIBio to develop and commercialize MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody. HIBio is a biotechnology company based in South San Francisco that focuses on discovering and…

Benzinga

What Does Elon Musk Mean By The Tesla Tech Tree? Inside A $5.5 Trillion Opportunity

Advice shared by Tesla Inc (NASDAQ: TSLA) CEO on Tuesday could help illustrate exactly how big of an opportunity the electric vehicle company has to expand into other verticals and how tough it is to value the company as a vehicle maker.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Intuitive Surgical Whale Trades Spotted

Someone with a lot of money to spend has taken a bullish stance on Intuitive Surgical (NASDAQ:ISRG). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Datadog Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Datadog. Looking at options history for Datadog (NASDAQ:DDOG) we detected 17 strange trades.

Benzinga

$100 Invested In Microchip Technology 20 Years Ago Would Be Worth This Much Today

Microchip Technology (NASDAQ:MCHP) has outperformed the market over the past 20 years by 1.04% on an annualized basis producing an average annual return of 7.85%. Currently, Microchip Technology has a market capitalization of $33.39 billion.

Benzinga

Check Out What Whales Are Doing With Micron Technology

A whale with a lot of money to spend has taken a noticeably bearish stance on Micron Technology. Looking at options history for Micron Technology (NASDAQ:MU) we detected 53 strange trades.

Benzinga

High Tide Clocks 98% Revenue Growth In Q2

High Tide Inc (NASDAQ:HITI) reported second-quarter revenue growth of 98% year-over-year to C$81.03 million, and loss per share improved to C$(0.14) from C$(0.30) in 2Q21. Geographically revenue of C$63.5 million was earned in Canada, C$15.9 million was earned in the United States, and $1.6 million was earned internationally. The gross profit margin…

Benzinga

4 Analysts Have This to Say About Leslies

Leslies (NASDAQ:LESL) has observed the following analyst ratings within the last quarter:

Benzinga

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,000 Today

Marriott Intl (NASDAQ:MAR) has outperformed the market over the past 10 years by 3.78% on an annualized basis producing an average annual return of 14.42%. Currently, Marriott Intl has a market capitalization of $49.85 billion.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Benchmark Downgrades AeroClean After Share Price Rallies

Benchmark analyst Robert Wasserman downgraded AeroClean Technologies Inc (NASDAQ:AERC) to Hold from Buy, without a price target. The analyst notes that despite a poor overall market outlook, the company's shares have quickly reached and exceeded earlier price targets. Wasserman downgraded the rating on AERC at this time due to share price and market volatility.…

Benzinga

Analyst Recommends Buying Apple, Microsoft And Google Stock, Citing This Investment Advice From Warren Buffett

The Nasdaq has led the broader markets lower since the start of the year as inflation concerns ripple through technology names. However, mega cap tech stocks have shown relative strength and one analyst sees opportunity in a few of the market giants.

Benzinga

Why Shorts May Go Up In Smoke As Nio Stock Charges Higher

Nio, Inc (NASDAQ: NIO) was soaring over 16% higher on Tuesday, reversing course from the 15% decline the stock took between Friday and Monday.

Benzinga

For The First Time There's A Rocket Capable Of Establishing Permanent Mars And Moon Bases: Elon Musk

A rocket capable of establishing a permanent presence on the moon and Mars has been built for the first time in history, according to Elon Musk — the CEO of private space giant SpaceX and electric vehicle manufacturer Tesla Inc.(NASDAQ: TSLA).

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Here's How Citi Views Amylyx Pharma

Citi Research has raised the price target on Amylyx Pharmaceuticals Inc's (NASDAQ:AMLX) to $33 from $32, with a Buy rating. It says the small market opportunity for the newly approved amyotrophic lateral sclerosis (ALS) drug in Canada (~$100 million peak) bodes well for ongoing FDA review. Availability in Canada and using ALSFRS-R data as the primary basis…

Benzinga

Netflix Goes Aggressive On Mobile Gaming, Interacts With Roku, Comcast Regarding Ad-Supported Service Tier

Netflix, Inc (NASDAQ:NFLX) released 23 mobile game titles since November and looked to double that number by year-end, the Variety quoted Leanne Loombe, Netflix's head of external games at the Tribeca Film Festival. Netflix's ambitions appear lofty amid layoffs and dipping stock prices prompted by a drop in subscribers that will likely take a harder…

Benzinga

Looking At Costco Wholesale's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Costco Wholesale (NASDAQ:COST). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,400 Today

Lululemon Athletica (NASDAQ:LULU) has outperformed the market over the past 10 years by 5.14% on an annualized basis producing an average annual return of 15.79%. Currently, Lululemon Athletica has a market capitalization of $35.62 billion.

Benzinga

What 4 Analyst Ratings Have To Say About Amylyx Pharma

Within the last quarter, Amylyx Pharma (NASDAQ:AMLX) has observed the following analyst ratings:

Benzinga

How Is The Market Feeling About Telefonaktiebolaget L M?

Telefonaktiebolaget L M's (NASDAQ:ERIC) short percent of float has fallen 32.14% since its last report. The company recently reported that it has 5.93 million shares sold short, which is 0.19% of all regular shares that are available for trading.

Benzinga

Here's How Much $1000 Invested In Lam Research 15 Years Ago Would Be Worth Today

Lam Research (NASDAQ:LRCX) has outperformed the market over the past 15 years by 9.12% on an annualized basis producing an average annual return of 15.33%. Currently, Lam Research has a market capitalization of $62.26 billion.

1 … 452 453 454 455

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.